{"content":"<li class=\"n-box-item date-title\" data-end=\"1500350399\" data-start=\"1500264000\" data-txt=\"Monday, December 23, 2019\">Monday, July 17, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3279067\" data-ts=\"1500331717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279067-retail-workers-union-opposes-amazon-whole-foods-combo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Retail workers union opposes Amazon-Whole Foods combo</a></h4><ul>     <li>The United Food and Commercial Workers Union <a href=\"http://www.reuters.com/article/us-wholefoods-m-a-amazon-unions-idUSKBN1A226I?il=0\" target=\"_blank\">comes out against</a> Amazon's (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) proposed purchase of Whole Foods (WFM), sendingt a letter to antitrust enforcers warning about the dangers of the $13.7B deal.</li>     <li>Union president Marc Perrone argues the takeover would hurt consumers by giving AMZN such power over suppliers that prices could go up while the quality and variety of products could be reduced.</li>     <li>Perrone also says the deal is \"not about improving customer service, products or choice. It is about destroying Whole Foods jobs through Amazon-style automation.\"</li>     <li>The UFCW represents ~800K clerks and other workers at other grocery chains but not WFM employees.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279067\" data-linked=\"Retail workers union opposes Amazon-Whole Foods combo\" data-tweet=\"$AMZN - Retail workers union opposes Amazon-Whole Foods combo https://seekingalpha.com/news/3279067-retail-workers-union-opposes-amazon-whole-foods-combo?source=tweet\" data-url=\"https://seekingalpha.com/news/3279067-retail-workers-union-opposes-amazon-whole-foods-combo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>80&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279066\" data-ts=\"1500331528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FND\" target=\"_blank\">FND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279066-floor-decorminus-5_5-starts-9m-share-secondary\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Floor &amp; Decor -5.5% as it starts 9M-share secondary</a></h4><ul>   <li>Floor &amp; Decor Holdings (NYSE:<a href='https://seekingalpha.com/symbol/FND' title='Floor & Decor Holdings, Inc.'>FND</a>) is <font color='red'>off 5.5%</font> after hours after <a href=\"https://seekingalpha.com/pr/16888583-floor-and-decor-holdings-inc-announces-launch-secondary-offering-preliminary-financial\" target=\"_blank\">launching a secondary offering</a> of 9M shares to be sold by certain stockholders.</li>    <li>Underwriters for the company's recent IPO (of 10.15M shares) are waiving lock-up restrictions with regard to these shares, and will replace with new 90-day lock-ups for officers, directors and certain other stockholders.</li>    <li>That's over $355M at today's closing price. Underwriters will have a 30-day greenshoe option to buy up to 1.35M shares from the stockholders. The company's not selling shares and won't see any proceeds.</li>    <li>BofA Merrill Lynch, Barclays, Credit Suisse, UBS, Goldman Sachs, Jefferies, Piper Jaffray and Wells Fargo Securities are joint book-runners.</li>    <li>Along with the offering notice, the company posted preliminary estimates for its quarter: net sales of $342M-$344M (above consensus for $334.4M), EPS of $0.19-$0.20 (vs. consensus for $0.18), and EBITDA of $41.7M-$43.7M (above an expected $41.2M).</li>    <li>It expects comparable-store sales growth of about 14.7%, vs. a year-ago 22.6%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279066\" data-linked=\"Floor &amp; Decor -5.5% as it starts 9M-share secondary\" data-tweet=\"$FND - Floor &amp; Decor -5.5% as it starts 9M-share secondary https://seekingalpha.com/news/3279066-floor-decorminus-5_5-starts-9m-share-secondary?source=tweet\" data-url=\"https://seekingalpha.com/news/3279066-floor-decorminus-5_5-starts-9m-share-secondary\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279065\" data-ts=\"1500330230\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNOM\" target=\"_blank\">VNOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279065-viper-energy-partners-to-launch-11m-unit-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viper Energy Partners to launch 11M-unit offering</a></h4><ul>     <li>Viper Energy Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/VNOM' title='Viper Energy Partners LP'>VNOM</a>) <font color='red'>-4.4%</font>&nbsp;AH after commencing an 11M-unit <a href=\"https://seekingalpha.com/pr/16888483-viper-energy-partners-lp-subsidiary-diamondback-energy-inc-announces-public-offering-common\" target=\"_blank\">public offering</a>, with an underwriters option to purchase up to an additional 1.65M common units.</li><li>VNOM says sponsor Diamondback Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/FANG' title='Diamondback Energy'>FANG</a>) has indicated its interest in purchasing up to 3..33M units in the offering.</li>     <li>VNOM plans to use the proceeds to pay down its revolving credit facility, fund part of its pending acquisitions and for general partnership purposes, which may include additional acquisitions.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279065\" data-linked=\"Viper Energy Partners to launch 11M-unit offering\" data-tweet=\"$VNOM $VNOM $FANG - Viper Energy Partners to launch 11M-unit offering https://seekingalpha.com/news/3279065-viper-energy-partners-to-launch-11m-unit-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3279065-viper-energy-partners-to-launch-11m-unit-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279061\" data-ts=\"1500327541\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279061-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a> <font color='green'>+10.7%</font>. <a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a> <font color='green'>+8.2%</font>. <a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a> <font color='green'>+5.6%</font>. <a href='https://seekingalpha.com/symbol/IMAX' title='IMAX Corporation'>IMAX</a> <font color='green'>+4.4%</font>. <a href='https://seekingalpha.com/symbol/NBR' title='Nabors Industries Ltd.'>NBR</a> <font color='green'>+3.3%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/MIXT' title='MiX Telematics Limited'>MIXT</a> <font color='red'>-10.3%</font>. <a href='https://seekingalpha.com/symbol/ETH' title='Ethan Allen Interiors Inc.'>ETH</a> <font color='red'>-4.6%</font>. <a href='https://seekingalpha.com/symbol/VNOM' title='Viper Energy Partners LP'>VNOM</a> <font color='red'>-4.4%</font>. SCSS <font color='red'>-4.0%</font>. <a href='https://seekingalpha.com/symbol/HCC' title='Warrior Met Coal'>HCC</a> <font color='red'>-3.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279061\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$NFLX $RAD $PRTK - After Hours Gainers / Losers https://seekingalpha.com/news/3279061-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3279061-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279055\" data-ts=\"1500325841\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REI\" target=\"_blank\">REI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279055-ring-energyminus-5-on-news-of-public-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ring Energy -5% on news of public offering</a></h4><ul><li>Ring Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/REI' title='Ring Energy, Inc.'>REI</a>) <font color='red'>-5.2%</font>&nbsp;AH after announcing a <a href=\"https://seekingalpha.com/pr/16888448-ring-energy-inc-announces-common-stock-offering\" target=\"_blank\">public offering</a> of an undisclosed size; the underwriters will have an option to purchase up to       an additional 15% of the common shares in the offering.</li><li>REI says it plans to use the proceeds to fund       its 2017 capex program and for general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279055\" data-linked=\"Ring Energy -5% on news of public offering\" data-tweet=\"$REI - Ring Energy -5% on news of public offering https://seekingalpha.com/news/3279055-ring-energyminus-5-on-news-of-public-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3279055-ring-energyminus-5-on-news-of-public-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279052\" data-ts=\"1500325597\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLY\" target=\"_blank\">NLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279052-along-capital-raise-annaly-reports-preliminary-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Along with capital raise, Annaly reports preliminary Q2 results</a></h4><ul><li><a href=\"https://seekingalpha.com/filing/3626957\" target=\"_blank\">Q2 core earnings</a> (excl. premium amortization adjustment) of $0.30 per share vs. $0.31 earned in Q1.</li><li>June 30, book value per share of $11.19 vs. $11.23 three months earlier. Today's close of $12.26 was a 9.5% premium to June 30 book.</li><li><a href='https://seekingalpha.com/symbol/NLY' title='Annaly Capital Management, Inc.'>NLY</a><font color='red'> -2.5%</font>&nbsp;after hours to $11.95.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3279026-annaly-hits-capital-raise-button-shares-almost-3-percent\" target=\"_blank\">Annaly hits the capital raise button; shares down almost 3%</a> (July 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279052\" data-linked=\"Along with capital raise, Annaly reports preliminary Q2 results\" data-tweet=\"$NLY - Along with capital raise, Annaly reports preliminary Q2 results https://seekingalpha.com/news/3279052-along-capital-raise-annaly-reports-preliminary-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3279052-along-capital-raise-annaly-reports-preliminary-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279011\" data-ts=\"1500324182\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBYI\" target=\"_blank\">PBYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279011-nasdaq-suspends-trading-in-puma-biotech\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nasdaq suspends trading in Puma Biotech</a></h4><ul><li>Nasdaq halted traded in Puma Biotechnology (<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='red'>-4%</font>) at 3:37 pm ET pending news.</li><li>Friday, July 21 is the FDA's action date for neratinib for HER2+ breast cancer.</li><li><strong>Update</strong>: The FDA <a href=\"https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm567259.htm?platform=hootsuite\" target=\"_blank\">approves </a>neratinib for the extended adjunctive treatment of early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant treatment with Roche's Herceptin (trastuzumab). Shares have yet to resume trading after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279011\" data-linked=\"Nasdaq suspends trading in Puma Biotech\" data-tweet=\"$PBYI - Nasdaq suspends trading in Puma Biotech https://seekingalpha.com/news/3279011-nasdaq-suspends-trading-in-puma-biotech?source=tweet\" data-url=\"https://seekingalpha.com/news/3279011-nasdaq-suspends-trading-in-puma-biotech\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279038\" data-ts=\"1500323855\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTK\" target=\"_blank\">PRTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279038-parateks-omadacycline-successful-in-late-stage-study-in-absssi-shares-ahead-7-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Paratek&#39;s omadacycline successful in late-stage study in ABSSSI; shares ahead 7% after hours</a></h4><ul><li>A Phase 3 clinical trial, OASIS-2, comparing Paratek Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a>) once-daily oral antibiotic omadacycline to twice-daily oral linezolid for the treatment of acute bacterial skin and skin structure infections ((ABSSSI)) <a href=\"https://seekingalpha.com/pr/16888415-paratek-announces-phase-3-study-oral-dosing-omadacycline-met-primary-secondary-fda-ema\" target=\"_blank\">met all primary and secondary endpoints</a>. It is the third successful late-stage study supporting the drug.</li><li>OASIS-2 demonstrated omadacycline's non-inferiority to linezolid in addition to high clinical success rates for infections caused by the most common ABSSSI pathogens, including MRSA.</li><li>Complete data will be presented at an upcoming scientific congress.</li><li>Shares are up&nbsp;<font color='green'>7%</font>&nbsp;after hours on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279038\" data-linked=\"Paratek&#39;s omadacycline successful in late-stage study in ABSSSI; shares ahead 7% after hours\" data-tweet=\"$PRTK - Paratek&#39;s omadacycline successful in late-stage study in ABSSSI; shares ahead 7% after hours https://seekingalpha.com/news/3279038-parateks-omadacycline-successful-in-late-stage-study-in-absssi-shares-ahead-7-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3279038-parateks-omadacycline-successful-in-late-stage-study-in-absssi-shares-ahead-7-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279031\" data-ts=\"1500323355\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279031-netflix-to-finance-heavy-content-spending-debt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix to finance heavy content spending with debt</a></h4><ul>   <li>Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) is flying after hours, <font color='green'>up 8.4%</font>, following a beat on revenues and some <a href=\"https://seekingalpha.com/news/3279019-netflix-jumps-8_2-percent-revenues-beat-subscriber-count-gets-jolt\" target=\"_blank\">subscriber numbers much stronger than expected</a>.</li>    <li>The company's above-consensus forecast for Q3 subscribers (4.4M vs. expected 3.99M) reflects some expectations that Q2 momentum will continue but tempered a bit as \"we are cognizant of the lessons of prior quarters when we over-forecasted and there was lumpiness in net adds, likely due to demand being pulled forward (into Q2 in this case).\"</li>    <li>Meanwhile, free cash flow is running out the door faster, at -$608M vs. a year-ago -$254M, and Q1's -$423M. \"With our content strategy paying off in strong member, revenue and profit growth, we think it&rsquo;s wise to continue to invest,\" it says, noting it expects FCF of -$2B to -$2.5B for 2017 and reiterates the company expects to be FCF negative for \"many years,\" fed by debt financing.</li>    <li>In a competitive look, the company says the market's broad enough for it to go from zero to 50M streaming households even as HBO keeps adding U.S. subs. \"It seems our growth just expands the market. The largely exclusive nature of each service&rsquo;s content means that we are not direct substitutes for each other, but rather complements.\"</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3279031\" data-linked=\"Netflix to finance heavy content spending with debt\" data-tweet=\"$NFLX - Netflix to finance heavy content spending with debt https://seekingalpha.com/news/3279031-netflix-to-finance-heavy-content-spending-debt?source=tweet\" data-url=\"https://seekingalpha.com/news/3279031-netflix-to-finance-heavy-content-spending-debt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>158&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279027\" data-ts=\"1500322876\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBAY\" target=\"_blank\">CBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279027-cymabay-readies-1_5m-share-stock-offering-shares-down-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CymaBay readies 1.5M-share stock offering; shares down 4% after hours</a></h4><ul><li>CymaBay Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics'>CBAY</a>) slips&nbsp;<font color='red'>4%</font>&nbsp;after hours on average volume in response to its <a href=\"https://seekingalpha.com/pr/16888451-cymabay-announces-proposed-public-offering-common-stock\" target=\"_blank\">planned public offering</a> of 1.5M shares of common stock. Price and terms have yet to be announced.</li><li>Net proceeds will fund the ongoing development of seladelpar, working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279027\" data-linked=\"CymaBay readies 1.5M-share stock offering; shares down 4% after hours\" data-tweet=\"$CBAY - CymaBay readies 1.5M-share stock offering; shares down 4% after hours https://seekingalpha.com/news/3279027-cymabay-readies-1_5m-share-stock-offering-shares-down-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3279027-cymabay-readies-1_5m-share-stock-offering-shares-down-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279026\" data-ts=\"1500322820\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLY\" target=\"_blank\">NLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279026-annaly-hits-capital-raise-button-shares-down-almost-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Annaly hits the capital raise button; shares down almost 3%</a></h4><ul><li>Its shares trading at a sizable premium to book value for the first time in a while, Annaly Capital (NYSE:<a href='https://seekingalpha.com/symbol/NLY' title='Annaly Capital Management, Inc.'>NLY</a>) is offering common shares for the first time in a while. The <a href=\"https://seekingalpha.com/pr/16888446-annaly-capital-management-inc-announces-public-offering-common-stock\" target=\"_blank\">secondary size is 60M shares</a>, with underwriter greenshoe option for another 9M shares.</li><li>Last reported (March 31) book value per share was $11.23. The stock closed today at $12.26.</li><li>Shares<font color='red'> -2.9%&nbsp;</font>after hours to $11.90.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279026\" data-linked=\"Annaly hits the capital raise button; shares down almost 3%\" data-tweet=\"$NLY - Annaly hits the capital raise button; shares down almost 3% https://seekingalpha.com/news/3279026-annaly-hits-capital-raise-button-shares-down-almost-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3279026-annaly-hits-capital-raise-button-shares-down-almost-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279019\" data-ts=\"1500322338\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279019-netflix-jumps-8_2-revenues-beat-subscriber-count-gets-jolt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix jumps 8.2% as revenues beat, subscriber count gets jolt</a></h4><ul>     <li>Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) is <font color='green'>up 8.2%</font> after hours after posting bullish subscriber numbers for Q2 and strong expectations for the coming quarter, and <a href=\"https://seekingalpha.com/news/3279017-netflix-misses-0_01-beats-revenue\" target=\"_blank\">beat expectations on revenue</a> despite a narrow profit miss.</li>     <li>It posted domestic net adds of 1.07M, well ahead of estimates for adding 633,000 subs. International streaming net adds came to 4.14M vs. an expected 2.63M.</li>     <li>Streaming membership sits at 104M, crossing a symbolic milestone of 100M users, and the company notes it has more international members (at 50.1% of base) than domestic members now.</li>     <li>The company forecasts total net streaming adds of 4.4M in Q3, vs. 3.99M expected. It sees Q3 international adds coming to 3.65M.</li>     <li>It's also guiding to Q3 revenues of $2.96B vs. consensus for $2.876B, and net income &#40;GAAP&#41; of $143M vs. consensus for $101.6M. Netflix expects its first ever annual profit contribution from international operations.</li>     <li><a href=\"https://www.youtube.com/netflixir\" target=\"_blank\">\"Earnings interview\"</a> to come at 6 p.m. ET.</li>     <li><a href=\"https://seekingalpha.com/pr/16888435-netflix-releases-second-quarter-2017-financial-results\" target=\"_blank\">Press release</a></li>     <li><a href=\"http://files.shareholder.com/downloads/NFLX/2872209061x0x949716/CFB029CB-65E5-43D3-A87D-998FEFAA64C0/Q2_17_Shareholder_Letter.pdf\" target=\"_blank\">Shareholder letter</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3279019\" data-linked=\"Netflix jumps 8.2% as revenues beat, subscriber count gets jolt\" data-tweet=\"$NFLX - Netflix jumps 8.2% as revenues beat, subscriber count gets jolt https://seekingalpha.com/news/3279019-netflix-jumps-8_2-revenues-beat-subscriber-count-gets-jolt?source=tweet\" data-url=\"https://seekingalpha.com/news/3279019-netflix-jumps-8_2-revenues-beat-subscriber-count-gets-jolt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>131&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279017\" data-ts=\"1500322094\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279017-netflix-misses-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix misses by $0.01, beats on revenue</a></h4><ul><li>Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>): Q2 EPS of $0.15 <font color='red'>misses by $0.01</font>.</li><li>Revenue of $2.79B (+32.2% Y/Y) <font color='green'>beats by $30M</font>.</li><li>Shares&nbsp;<font color='green'>+7% AH</font>.</li><li><a href=\"https://seekingalpha.com/pr/16888435-netflix-releases-second-quarter-2017-financial-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279017\" data-linked=\"Netflix misses by $0.01, beats on revenue\" data-tweet=\"$NFLX - Netflix misses by $0.01, beats on revenue https://seekingalpha.com/news/3279017-netflix-misses-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3279017-netflix-misses-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279006\" data-ts=\"1500319549\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279006-musk-clarifies-place-bets-accordingly\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Musk clarifies: &#39;Place bets accordingly&#39;</a></h4><ul><li>Holding court at the National Governors Association meeting this weekend, Elon Musk <a href=\"http://markets.businessinsider.com/news/stocks/tesla-stock-price-is-moving-lower-after-elon-musk-says-company-is-higher-than-it-deserves-2017-7-1002179263?utm_content=buffer82d64&amp;utm_medium=social&amp;utm_source=twitter.com&amp;utm_campaign=buffer\" target=\"_blank\">made some news</a> saying (again) that Tesla's (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) stock price is too high.</li><li>The comments, along with news of a supposed autopilot failure in a Minnesota crash, helped send Tesla lower by nearly 4% this morning.</li><li>Musk, however,<a href=\"https://twitter.com/elonmusk/status/887027300042104832\" target=\"_blank\"> took to Twitter a few minutes ago</a> to clarify, calling the price high based on past and present, \"but low if you believe is Tesla's future. Place bets accordingly.\"</li><li>Shares remain<font color='red'> lower by 2.5%</font>&nbsp;on the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279006\" data-linked=\"Musk clarifies: &#39;Place bets accordingly&#39;\" data-tweet=\"$TSLA - Musk clarifies: &#39;Place bets accordingly&#39; https://seekingalpha.com/news/3279006-musk-clarifies-place-bets-accordingly?source=tweet\" data-url=\"https://seekingalpha.com/news/3279006-musk-clarifies-place-bets-accordingly\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>119&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279001\" data-ts=\"1500318046\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279001-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CRDS' title='Crossroads Systems, Inc.'>CRDS</a> <font color='green'>+77%</font>. <a href='https://seekingalpha.com/symbol/SEV' title='Sevcon, Inc.'>SEV</a> <font color='green'>+59%</font>. <a href='https://seekingalpha.com/symbol/QBAK' title='Qualstar Corporation'>QBAK</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/IDSY' title='I.D. Systems, Inc.'>IDSY</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/MOSY' title='MoSys, Inc.'>MOSY</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/VSLR' title='Vivint Solar'>VSLR</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279001\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$CRDS $SEV $QBAK - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3279001-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3279001-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278997\" data-ts=\"1500317072\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHGE\" target=\"_blank\">BHGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278997-two-analysts-launch-coverage-of-baker-hughes-one-buy-one-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Two analysts launch coverage of Baker Hughes: One buy, one neutral</a></h4><ul>     <li>Baker Hughes (<a href='https://seekingalpha.com/symbol/BHGE' title='Baker Hughes, a GE company'>BHGE</a> <font color='green'>+1.5%</font>) bumps higher after Morgan&nbsp;Stanley resumes coverage at Overweight with a <a href=\"http://www.barrons.com/articles/baker-hughes-analyst-initiations-one-yea-one-maybe-1500299299\" target=\"_blank\">Street-high $60 price target</a>, saying the \"lower cyclicality\" and strong free cash flow should \"re-rate\" the stock.</li>     <li>BHGE&rsquo;s integrated offering and financing capability places BHGE in the same \"weight class\" as other \"big gorillas\" including Schlumberger (NYSE:<a href='https://seekingalpha.com/symbol/SLB' title='Schlumberger Limited'>SLB</a>) and TechnipFMC, according to Stanley analyst Ole Slorer; this, combined with GE's manufacturing footprint, capital discipline and financing capability, has the potential to create a formidable competitor.</li>     <li>FBR Capital's Thomas Curran also initiates coverage but with a more cautious Market Perform rating and $42 price target, believe BHGE has inferior exposure to the most attractive investment themes as opposed to other large-cap options.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278997\" data-linked=\"Two analysts launch coverage of Baker Hughes: One buy, one neutral\" data-tweet=\"$BHGE $BKR $SLB - Two analysts launch coverage of Baker Hughes: One buy, one neutral https://seekingalpha.com/news/3278997-two-analysts-launch-coverage-of-baker-hughes-one-buy-one-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3278997-two-analysts-launch-coverage-of-baker-hughes-one-buy-one-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278989\" data-ts=\"1500314733\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278989-tesla-driver-autopilot-disengaged-time-of-crash\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla driver: Autopilot disengaged at time of crash</a></h4><ul><li><a href=\"http://www.reuters.com/article/tesla-autopilot-idUSL1N1K80VI\" target=\"_blank\">via Reuters</a></li><li>In an email, the driver of the Tesla (<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a> <font color='red'>-2.7%</font>) involved in the Minnesota incident said it's his belief that he disengaged the car's autopilot system prior to the crash.</li><li>Tesla remains nicely lower on the session, but off of its worst levels.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3278939-tesla-another-3-percent-autopilot-blamed-minnesota-incident\" target=\"_blank\">Tesla down another 3%; autopilot blamed after Minnesota incident</a> (July 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3278989\" data-linked=\"Tesla driver: Autopilot disengaged at time of crash\" data-tweet=\"$TSLA - Tesla driver: Autopilot disengaged at time of crash https://seekingalpha.com/news/3278989-tesla-driver-autopilot-disengaged-time-of-crash?source=tweet\" data-url=\"https://seekingalpha.com/news/3278989-tesla-driver-autopilot-disengaged-time-of-crash\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>119&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278987\" data-ts=\"1500314707\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278987-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NADL' title='North Atlantic Drilling Ltd.'>NADL</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/HBM' title='Hudbay Minerals Inc Ordinary Sh'>HBM</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/BAK' title='Braskem S.A.'>BAK</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/CCLP' title='CSI Compressco LP'>CCLP</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278987\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$NADL $HBM $YUMA - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3278987-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3278987-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278990\" data-ts=\"1500314367\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORIG\" target=\"_blank\">ORIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278990-ocean-rigplus-11-lundin-extends-drillrig-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ocean Rig +11% as Lundin extends drillrig contract</a></h4><ul>     <li>Ocean Rig UDW&nbsp;(<a href='https://seekingalpha.com/symbol/ORIG' title='Ocean Rig UDW Inc.'>ORIG</a> <font color='green'>+11.6%</font>) is higher after Lundin Norway <a href=\"http://www.offshoreenergytoday.com/lundin-extends-contract-for-ocean-rig-semi-sub/\" target=\"_blank\">renews its contract</a> for ORIG's <em>Leiv Eriksson</em> semi-submersible drilling rig through Sept. 30 with options to drill two more wells in the future.</li>     <li>If fully exercised, the options would extend the contract through early 2019 with a backlog of up to $85M.</li>     <li>Lundin was granted a drilling permit for another Alta appraisal well to be drilled with the&nbsp;<em>Leiv Eiriksson</em> rig.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278990\" data-linked=\"Ocean Rig +11% as Lundin extends drillrig contract\" data-tweet=\"$ORIG - Ocean Rig +11% as Lundin extends drillrig contract https://seekingalpha.com/news/3278990-ocean-rigplus-11-lundin-extends-drillrig-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3278990-ocean-rigplus-11-lundin-extends-drillrig-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278985\" data-ts=\"1500314111\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278985-pareteumminus-9_4-on-warrant-exercise-agreement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum -9.4% on warrant exercise agreement</a></h4><ul>    <li>Pareteum's (NYSEMKT:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) on a roller coaster ride today -- <font color='green'>up as much as 25%</font> premarket today (after Friday's <a href=\"https://seekingalpha.com/news/3278761-pareteum-plus-7-percent-sees-extension-nyse-compliance\" target=\"_blank\">listing compliance news</a>), shares are <font color='red'>down 9.4%</font> after an <a href=\"https://seekingalpha.com/filing/3626486\" target=\"_blank\">8-K filed a minute after today's open</a>.</li>    <li>According to the filing, the company's entered into warrant exercise agreements with holders of warrants allowing for the purchase of up to 1.15M shares at $1.87/share, that provides for holders to exercise those warrants at a reduced price of $1.00/share.</li>    <li>The stock had closed at $1.38 Friday and opened at $1.74 today.</li>    <li>In consideration for exercising the original warrants at the lower price, holders would get a new warrant with an exercise price of $1.39, exercisable after six months from now.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278985\" data-linked=\"Pareteum -9.4% on warrant exercise agreement\" data-tweet=\"$TEUM - Pareteum -9.4% on warrant exercise agreement https://seekingalpha.com/news/3278985-pareteumminus-9_4-on-warrant-exercise-agreement?source=tweet\" data-url=\"https://seekingalpha.com/news/3278985-pareteumminus-9_4-on-warrant-exercise-agreement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278981\" data-ts=\"1500312694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278981-financials-top-5-gainers-losers-of-1-30-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:30 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RLJ' title='RLJ Lodging Trust'>RLJ</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/EQBK' title='Equity Bancshares'>EQBK</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/QIWI' title='QIWI plc'>QIWI</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CIGI' title='Colliers International Group Inc.'>CIGI</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278981\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:30 PM\" data-tweet=\"$RLJ $EQBK $QIWI - Financials - Top 5 Gainers / Losers as of 1:30 PM https://seekingalpha.com/news/3278981-financials-top-5-gainers-losers-of-1-30-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3278981-financials-top-5-gainers-losers-of-1-30-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278977\" data-ts=\"1500311454\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDC\" target=\"_blank\">DDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278977-rio-tinto-deal-for-dominion-diamond-cannot-be-ruled-out-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rio Tinto deal for Dominion Diamond cannot be ruled out, analyst says</a></h4><ul><li>Dominion Diamond (<a href='https://seekingalpha.com/symbol/DDC' title='Dominion Diamond Corporation'>DDC</a> <font color='green'>+4.2%</font>) could accept a higher offer than Washington Companies&rsquo; <a href=\"https://seekingalpha.com/news/3278885-dominion-diamond-taken-private-1_2b-deal\" target=\"_blank\">$14.25/share buyout offer</a>, but it is difficult to  see who else might get involved aside from Rio Tinto (<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color='green'>+1%</font>), who is the JV  partner at DDC's Diavik mine, BMO analyst Edward Sterck writes.</li><li>Rio&rsquo;s involvement cannot be ruled out, but management may feel that  after finishing up a period of asset shedding, an initial deal in the diamond industry may not be digestible for its investors, Streck says.</li><li>Scotiabank has said previously that Rio could be &ldquo;logically be interested&rdquo; in DDC given significant synergy potential.</li><li>Source:&nbsp;Bloomberg First Word</li></ul><div class=\"tiny-share-widget\" data-id=\"3278977\" data-linked=\"Rio Tinto deal for Dominion Diamond cannot be ruled out, analyst says\" data-tweet=\"$DDC $DDC $RIO - Rio Tinto deal for Dominion Diamond cannot be ruled out, analyst says https://seekingalpha.com/news/3278977-rio-tinto-deal-for-dominion-diamond-cannot-be-ruled-out-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3278977-rio-tinto-deal-for-dominion-diamond-cannot-be-ruled-out-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278976\" data-ts=\"1500311311\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNGX\" target=\"_blank\">SNGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278976-wainwright-likes-soligenix-sees-four-bagger-shares-ahead-29\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wainwright likes Soligenix, sees a four-bagger; shares ahead 29%</a></h4><ul><li>Thinly traded nano cap Soligenix (<a href='https://seekingalpha.com/symbol/SNGX' title='Soligenix, Inc.'>SNGX</a> <font color='green'>+28.7%</font>) is up on a whopping 46x surge in volume. Earlier today, H.C. Wainwright initiated coverage with a Buy rating and $11 price target.</li><li>The company has three programs in late-stage development: <a href=\"http://www.soligenix.com/pipeline/biotherapeutics/sgx301-for-the-treatment-of-cutaneous-t-cell-lymphoma/\" target=\"_blank\">SGX301</a>, a topical photosensitizing agent for the treatment of cutaneous T-cell lymphoma, <a href=\"http://www.soligenix.com/pipeline/biotherapeutics/sgx203-oral-bdp-for-treating-pediatric-crohns-disease/\" target=\"_blank\">SGX203</a>, an orally available steroid for the treatment of pediatric Crohn's disease and <a href=\"http://www.soligenix.com/pipeline/biotherapeutics/sgx942-oral-mucositis/\" target=\"_blank\">SGX942</a>, a synthetic peptide for the treatment of chemoradiation-associated oral mucositis.</li><li>Three programs have Fast Track status in the U.S.: SGX942, ricin toxin vaccine <a href=\"http://www.soligenix.com/pipeline/vaccinesbiodefense/rivax-ricin-toxin-vaccine/\" target=\"_blank\">RiVax </a>and <a href=\"http://www.soligenix.com/pipeline/vaccinesbiodefense/orbeshield-for-gastrointestinal-acute-radiation-syndrome-gi-ars/\" target=\"_blank\">OrbeShield</a>, an orally administered steroid for GI acute radiation syndrome.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278976\" data-linked=\"Wainwright likes Soligenix, sees a four-bagger; shares ahead 29%\" data-tweet=\"$SNGX - Wainwright likes Soligenix, sees a four-bagger; shares ahead 29% https://seekingalpha.com/news/3278976-wainwright-likes-soligenix-sees-four-bagger-shares-ahead-29?source=tweet\" data-url=\"https://seekingalpha.com/news/3278976-wainwright-likes-soligenix-sees-four-bagger-shares-ahead-29\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278973\" data-ts=\"1500310794\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TELNY\" target=\"_blank\">TELNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278973-telenorplus-9_3-on-earnings-beat-30m-share-buyback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Telenor +9.3% on earnings beat, 30M-share buyback</a></h4><ul>   <li>Telenor (<a href='https://seekingalpha.com/symbol/TELNY' title='Telenor ASA ADR'>OTCPK:TELNY</a>) has <font color='green'>jumped 9.3%</font> in U.S. trading after posting a <a href=\"https://seekingalpha.com/news/3278846-telenor-asa-reports-q2-results\" target=\"_blank\">narrower loss</a> than expected in Q2 and setting a buyback of up to 30M shares.</li>    <li>Revenues of 31.47B Norwegian kroner beat an expected 31.21B, showing organic growth of 2.1%, and EBITDA of 12.72B kroner (up 12%) beat consensus for 11.675B.</li>    <li>EPS loss on a GAAP basis was 0.11 kroner, vs. expectations for a loss of 0.44 kroner.</li>    <li>Free cash flow came to 9.95B kroner, up substantially from a year-ago 497M kroner.</li>    <li>With \"proceeds from recent transactions combined with a solid balance sheet,\" the company set a 2% share buyback.</li>    <li>For 2017, it's boosting EBITDA margin guidance to 38-39% from a previous 37%. It still sees organic revenue growth of 1-2%.</li>    <li><a href=\"https://www.telenor.com/media/press-release/telenor-reports-strong-results-and-solid-cash-flow-in-second-quarter-2017/\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3278973\" data-linked=\"Telenor +9.3% on earnings beat, 30M-share buyback\" data-tweet=\"$TELNY $TELNF - Telenor +9.3% on earnings beat, 30M-share buyback https://seekingalpha.com/news/3278973-telenorplus-9_3-on-earnings-beat-30m-share-buyback?source=tweet\" data-url=\"https://seekingalpha.com/news/3278973-telenorplus-9_3-on-earnings-beat-30m-share-buyback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278971\" data-ts=\"1500309695\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278971-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CRDS' title='Crossroads Systems, Inc.'>CRDS</a> <font color='green'>+74%</font>. <a href='https://seekingalpha.com/symbol/SEV' title='Sevcon, Inc.'>SEV</a> <font color='green'>+59%</font>. <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/SNGX' title='Soligenix, Inc.'>SNGX</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/DAC' title='Danaos Corporation'>DAC</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/QBAK' title='Qualstar Corporation'>QBAK</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics'>CBAY</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CGI' title='Celadon Group, Inc.'>CGI</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/QDEL' title='Quidel Corporation'>QDEL</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/BGC' title='General Cable Corporation'>BGC</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/QIWI' title='QIWI plc'>QIWI</a> <font color='red'>-11%</font>. PPHM <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/STON' title='StoneMor Partners L.P.'>STON</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/AMC' title='AMC Entertainment Holdings, Inc'>AMC</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD'>TXMD</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/AIRT' title='Air T, Inc.'>AIRT</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278971\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$CRDS $SEV $ACRX - Midday Gainers / Losers https://seekingalpha.com/news/3278971-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3278971-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278968\" data-ts=\"1500308880\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICPT\" target=\"_blank\">ICPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278968-intercept-pharma-under-modest-pressure-on-cymabay-seladelpar-data-shares-down-fraction\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intercept Pharma under modest pressure on CymaBay seladelpar data; shares down a fraction</a></h4><ul><li>Intercept Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a> <font color='red'>-0.4%</font>) slips on average volume. Shares were down almost&nbsp;<font color='red'>2%</font>&nbsp;before recovering after CymaBay Therapeutics announced encouraging results from a mid-stage stage study of fally liver disease candidate seladelpar.</li><li>Intercept's NASH candidate is obeticholic acid, in Phase 3 testing. It was approved in the EU in December 2016 for primary biliary cirrhosis.</li><li>NASH-related tickers: (<a href='https://seekingalpha.com/symbol/CANF' title='Can-Fite Biopharma Ltd'>CANF</a> <font color='red'>-0.5%</font>)(<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color='green'>+1.1%</font>)(<a href='https://seekingalpha.com/symbol/IMRN' title='Immuron Limited'>IMRN</a> <font color='red'>-2.2%</font>)(<a href='https://seekingalpha.com/symbol/CNAT' title='Conatus Pharmaceuticals'>CNAT</a> <font color='green'>+0.3%</font>)(<a href='https://seekingalpha.com/symbol/GNFTF' title='Genfit'>OTCPK:GNFTF</a>)(<a href='https://seekingalpha.com/symbol/MDGL' title='Madrigal Pharmaceuticals, Inc.'>MDGL</a> <font color='green'>+0.4%</font>)(<a href='https://seekingalpha.com/symbol/VKTX' title='Viking Therapeutics'>VKTX</a>)(<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='green'>+1.6%</font>)(<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>)(<a href='https://seekingalpha.com/symbol/DRRX' title='Durect Corporation'>DRRX</a> <font color='green'>+2.6%</font>)(<a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3278911-cymbays-seladelpar-shows-positive-treatment-effect-mid-stage-pbc-study-shares-ahead-17\" target=\"_blank\">CymBay's seladelpar shows positive treatment effect in mid-stage PBC study; shares ahead 17% premarket</a> (July 17)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3230483-intercept-pharmas-obeticholic-acid-okd-europe-primary-biliary-cirrhosis\" target=\"_blank\">Intercept Pharma's obeticholic acid OK'd in Europe for primary biliary cirrhosis</a> (Dec. 14, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3278968\" data-linked=\"Intercept Pharma under modest pressure on CymaBay seladelpar data; shares down a fraction\" data-tweet=\"$ICPT $ICPT $CANF - Intercept Pharma under modest pressure on CymaBay seladelpar data; shares down a fraction https://seekingalpha.com/news/3278968-intercept-pharma-under-modest-pressure-on-cymabay-seladelpar-data-shares-down-fraction?source=tweet\" data-url=\"https://seekingalpha.com/news/3278968-intercept-pharma-under-modest-pressure-on-cymabay-seladelpar-data-shares-down-fraction\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278966\" data-ts=\"1500307335\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278966-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/CRWS' title='Crown Crafts, Inc.'>CRWS</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/RIBT' title='RiceBran Technologies'>RIBT</a> <font color='green'>+6%.</font></li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='red'>-15%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278966\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$PME $CRWS $RIBT - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3278966-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3278966-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278963\" data-ts=\"1500307039\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278963-copper-climbs-past-6k-ton-on-upbeat-china-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Copper climbs past $6K/ton on upbeat China data</a></h4><ul>     <li>Mining stocks are on the move as <a href=\"https://www.ft.com/content/7a2417ec-b011-3e6c-b667-e3cb96056389?mhq5j=e2\" target=\"_blank\">copper prices rise above $6K/metric ton</a> for the first time since March after the Chinese government said its <a href=\"https://seekingalpha.com/news/3278828-china-maintains-gdp-growth-rate\" target=\"_blank\">GDP expanded at a 6.9% annual rate</a> in Q2 and industrial production growth of 7.6% beat expectations.</li>     <li>Freeport McMoran (<a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a> <font color='green'>+4.6%</font>) is up more than 4%, while Antofagasta (<a href='https://seekingalpha.com/symbol/ANFGF' title='Antofagasta plc'>OTC:ANFGF</a> <font color='green'>+4%</font>) also is headed higher.</li>     <li>A weak U.S. dollar, which earlier hit a 10-month low against a basket of other commodities, adds support to copper and commodity prices including aluminum, lead, zinc and nickel.</li>     <li>Meanwhile in the U.S., Reuters reports <a href=\"http://www.reuters.com/article/us-usa-copper-idUSKBN1A20L1\" target=\"_blank\">Comex copper stockpiles are set to rise</a> from their current 13-year highs because China is buying more scrap metal.</li>     <li>\"We&rsquo;ve had the build up but we have not yet had the run down, which means that demand hasn't come yet,\" says Barclays metals analyst Dane Davis.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/JJC' title='iPath Series B Bloomberg Copper Subindex Total Return ETN'>JJC</a>, <a href='https://seekingalpha.com/symbol/DBB' title='Invesco DB Base Metals ETF'>DBB</a>, <a href='https://seekingalpha.com/symbol/CPER' title='United States Copper Index ETF'>CPER</a>, <a href='https://seekingalpha.com/symbol/BOM' title='DB Base Metals Double Short ETN'>BOM</a>, <a href='https://seekingalpha.com/symbol/BOS' title='DB Base Metals Short ETN'>BOS</a>, <a href='https://seekingalpha.com/symbol/JJM' title='iPath DJ-UBS Industrial Metals Total Return Sub-Index ETN'>JJM</a>, <a href='https://seekingalpha.com/symbol/CUPM' title='iPath Pure Beta Copper ETN'>CUPM</a>, <a href='https://seekingalpha.com/symbol/BDD' title='DB Base Metals Double Long ETN'>BDD</a>, <a href='https://seekingalpha.com/symbol/RJZ' title='ELEMENTS Rogers International Commodity Metal ETN'>RJZ</a>, <a href='https://seekingalpha.com/symbol/BDG-OLD' title='DB Base Metals Long ETN'>BDG-OLD</a>, <a href='https://seekingalpha.com/symbol/UBM' title='UBS ETRACS CMCI Industrial Metals Total Return ETN'>UBM</a>, <a href='https://seekingalpha.com/symbol/HEVY' title='iPath Pure Beta Industrial Metals ETN'>HEVY</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3278963\" data-linked=\"Copper climbs past $6K/ton on upbeat China data\" data-tweet=\"$FCX $FCX $ANFGF - Copper climbs past $6K/ton on upbeat China data https://seekingalpha.com/news/3278963-copper-climbs-past-6k-ton-on-upbeat-china-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3278963-copper-climbs-past-6k-ton-on-upbeat-china-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278962\" data-ts=\"1500306673\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WP\" target=\"_blank\">WP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278962-vantiv-down-3-capital-forum-takes-aim-global-payments-dips\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vantiv down 3% as Capital Forum takes aim; Global Payments dips</a></h4><ul><li>via Bloomberg's Lily Katz</li><li>Vantiv's (VNTV <font color='red'>-2.9%</font>) billing approach is \"especially deceptive,\" <a href=\"https://thecapitolforum.com/\" target=\"_blank\">says Capital Forum</a>, noting the markup of interchange fees as making it difficult for merchants to see how much they're being charged.</li><li>Down alongside is Global Payments (<a href='https://seekingalpha.com/symbol/GPN' title='Global Payments Inc.'>GPN</a> <font color='red'>-2.2%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3278962\" data-linked=\"Vantiv down 3% as Capital Forum takes aim; Global Payments dips\" data-tweet=\"$WP $WP $GPN - Vantiv down 3% as Capital Forum takes aim; Global Payments dips https://seekingalpha.com/news/3278962-vantiv-down-3-capital-forum-takes-aim-global-payments-dips?source=tweet\" data-url=\"https://seekingalpha.com/news/3278962-vantiv-down-3-capital-forum-takes-aim-global-payments-dips\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278961\" data-ts=\"1500306572\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WVE\" target=\"_blank\">WVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278961-wave-launches-studies-investigating-two-pipeline-candidates-in-huntingtons-disease-shares-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wave launches studies investigating two pipeline candidates in Huntington&#39;s disease; shares up 2%</a></h4><ul><li>Wave Life Sciences (<a href='https://seekingalpha.com/symbol/WVE' title='Wave Life Sciences'>WVE</a> <font color='green'>+1.8%</font>) <a href=\"https://seekingalpha.com/pr/16887623-wave-life-sciences-initiates-two-phase-1b-2a-clinical-trials-precision-hd1-precision-hd2\" target=\"_blank\">initiates </a>two Phase 1b/2a studies, PRECISION-HD1 and PRECISION-HD2, assessing candidates WVE-120101 and WVE-120102, respectively, in patients with Huntington's disease &#40;HD&#41;. The studies will assess the safety and tolerability of single and multiple doses of both administered directly into the spinal canal (intrathecally). Other exploratory objectives include assessing the impact of each antisense oligonucleotide on the toxic mutant protein that causes the loss of brain cells in HD sufferers.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278961\" data-linked=\"Wave launches studies investigating two pipeline candidates in Huntington&#39;s disease; shares up 2%\" data-tweet=\"$WVE - Wave launches studies investigating two pipeline candidates in Huntington&#39;s disease; shares up 2% https://seekingalpha.com/news/3278961-wave-launches-studies-investigating-two-pipeline-candidates-in-huntingtons-disease-shares-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3278961-wave-launches-studies-investigating-two-pipeline-candidates-in-huntingtons-disease-shares-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278955\" data-ts=\"1500305458\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDT\" target=\"_blank\">MDT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278955-medtronic-fq1-revenues-low-end-of-guidance-earnings-high-end-shares-down-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medtronic FQ1 revenues at low end of guidance, earnings at high end; shares down 1%</a></h4><ul><li>In an interview with Bloomberg, Medtronic (<a href='https://seekingalpha.com/symbol/MDT' title='Medtronic plc'>MDT</a> <font color='red'>-1.1%</font>) CFO Karen Parkhill said fiscal Q1 constant currency sales will be in the low end of guidance due to a computer crash, but the company still expects to achieve its guidance of 4 - 5% growth for the year. FQ1 earnings should be in the upper range of its high-single-digit&nbsp;guidance.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3278955\" data-linked=\"Medtronic FQ1 revenues at low end of guidance, earnings at high end; shares down 1%\" data-tweet=\"$MDT - Medtronic FQ1 revenues at low end of guidance, earnings at high end; shares down 1% https://seekingalpha.com/news/3278955-medtronic-fq1-revenues-low-end-of-guidance-earnings-high-end-shares-down-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3278955-medtronic-fq1-revenues-low-end-of-guidance-earnings-high-end-shares-down-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278954\" data-ts=\"1500304863\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDVX\" target=\"_blank\">MDVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278954-medovex-secures-2_7m-in-new-capital-via-direct-offering-private-placement-of-stock-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medovex secures $2.7M in new capital via direct offering/private placement of stock and warrants; shares up 2%</a></h4><ul><li>Thinly traded nano cap Medovex (<a href='https://seekingalpha.com/symbol/MDVX' title='Medovex Inc.'>OTC:MDVX</a> <font color='green'>+1.9%</font>) <a href=\"https://seekingalpha.com/pr/16887726-medovex-corporation-announces-pricing-2_69-million-concurrent-registered-direct-offering\" target=\"_blank\">raises $2.69M in new capital</a> via the direct sale of 2,956,043 shares of common stock at $0.91 per share and a concurrent private placement of five-year warrants to purchase up to 1,478,022 shares of common at $1.15.</li><li>Net proceeds will fund working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278954\" data-linked=\"Medovex secures $2.7M in new capital via direct offering/private placement of stock and warrants; shares up 2%\" data-tweet=\"$MDVX $HCYT - Medovex secures $2.7M in new capital via direct offering/private placement of stock and warrants; shares up 2% https://seekingalpha.com/news/3278954-medovex-secures-2_7m-in-new-capital-via-direct-offering-private-placement-of-stock-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3278954-medovex-secures-2_7m-in-new-capital-via-direct-offering-private-placement-of-stock-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278953\" data-ts=\"1500304840\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBX\" target=\"_blank\">GBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278953-greenbrier-upgraded-to-buy-stifel-rail-fundamentals-seen-improving\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Greenbrier upgraded to Buy at Stifel as rail fundamentals seen improving</a></h4><ul>     <li>Greenbrier (<a href='https://seekingalpha.com/symbol/GBX' title='The Greenbrier Companies, Inc.'>GBX</a> <font color='green'>+6%</font>) jumps as much as 7% after Stifel <a href=\"http://thefly.com/thestreet/realmoney/index.php/GBXid2578773/GBX-Greenbrier-upgraded-on-recent-deals-results-at-Stifel\" target=\"_blank\">upgrades shares to Buy</a> from Hold with a $51 price target, raised from $48, saying GBX is now a \"significantly stronger\" company and the market may be  underestimating the cumulative benefit of several recent deals to grow and diversify the business.</li>     <li>GBX has been weak since reporting <a href=\"https://seekingalpha.com/news/3276190-greenbriers-q3\" target=\"_blank\">FQ3 results</a> last month, as guidance implied a significant step-down in earnings for Q4, but Stifel sees conditions in North America starting to improve modestly and believes GBX's execution in a difficult market has been impressive.</li>     <li>Despite anticipated margin headwinds next year, the firm thinks GBX's deal with MUL and international expansion will support EPS growth in  2018, which should drive shares higher.</li>     <li>Stifel also upgrades GATX (<a href='https://seekingalpha.com/symbol/GATX' title='GATX Corp.'>GATX</a> <font color='green'>+3.8%</font>) to Hold from Sell, saying railcar leasing fundamentals should show stability in Q2, while cutting Wabtec (<a href='https://seekingalpha.com/symbol/WAB' title='Westinghouse Air Brake Technologies Corporation'>WAB</a> <font color='green'>+0.2%</font>) to Hold from Buy as valuation appears full following recent strength in the shares.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278953\" data-linked=\"Greenbrier upgraded to Buy at Stifel as rail fundamentals seen improving\" data-tweet=\"$GBX $GBX $GATX - Greenbrier upgraded to Buy at Stifel as rail fundamentals seen improving https://seekingalpha.com/news/3278953-greenbrier-upgraded-to-buy-stifel-rail-fundamentals-seen-improving?source=tweet\" data-url=\"https://seekingalpha.com/news/3278953-greenbrier-upgraded-to-buy-stifel-rail-fundamentals-seen-improving\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278951\" data-ts=\"1500304201\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278951-black-monday-in-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">&#39;Black Monday&#39; in China</a></h4><ul><li>There's little major damage to be seen in the Shanghai Composite, which&nbsp;<font color='red'>fell 1.4%</font>&nbsp;overnight, <a href=\"http://www.scmp.com/business/markets/article/2102983/china-stocks-plunge-black-monday-nearly-500-stocks-falling-daily\" target=\"_blank\">but nearly 500 names in China </a>tumbled their&nbsp;<font color='red'>daily limit of 10%</font>, and more than 1.2K in Shanghai and Shenzhen&nbsp;<font color='red'>slid over 7%</font>.</li><li>Shenzhen - &nbsp;more tied to smaller-cap stocks - fared worst, with the Composite Index there&nbsp;<font color='red'>down 4.3%</font>.</li><li>Some local analysts are dubbing it \"Black Monday.\"</li><li>Over the weekend at a financial conference chaired by President Xi Jinping, policymakers talked a tough line on deleveraging and regulation.</li><li>China small-cap A-shares ETFs are hardest hit: <a href='https://seekingalpha.com/symbol/CNXT' title='VanEck Vectors ChinaAMC SME-ChiNext ETF'>CNXT</a>&nbsp;<font color='red'>-3.7%</font>, <a href='https://seekingalpha.com/symbol/ASHS' title='Deutsche X-trackers Harvest CSI 500 China-A Shares Small Cap ETF'>ASHS</a>&nbsp;<font color='red'>-4.4%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/FXI' title='iShares China Large-Cap ETF'>FXI</a>, <a href='https://seekingalpha.com/symbol/ASHR' title='Deutsche X-trackers Harvest CSI 300 China A-Shares ETF'>ASHR</a>, <a href='https://seekingalpha.com/symbol/YINN' title='Direxion Daily FTSE China Bull 3x Shares ETF'>YINN</a>, <a href='https://seekingalpha.com/symbol/CAF' title='Morgan Stanley China A Share Fund'>CAF</a>, <a href='https://seekingalpha.com/symbol/KWEB' title='KraneShares CSI China Internet ETF'>KWEB</a>, <a href='https://seekingalpha.com/symbol/YANG' title='Direxion Daily FTSE China Bear 3x Shares ETF'>YANG</a>, <a href='https://seekingalpha.com/symbol/GXC' title='SPDR S&P China ETF'>GXC</a>, <a href='https://seekingalpha.com/symbol/FXP' title='ProShares UltraShort FTSE China 25 ETF'>FXP</a>, <a href='https://seekingalpha.com/symbol/PGJ' title='PowerShares Golden Dragon China Portfolio ETF'>PGJ</a>, <a href='https://seekingalpha.com/symbol/MCHI' title='iShares MSCI China ETF'>MCHI</a>, <a href='https://seekingalpha.com/symbol/HAO' title='Guggenheim China Small Cap ETF'>HAO</a>, <a href='https://seekingalpha.com/symbol/CQQQ' title='Guggenheim China Technology ETF'>CQQQ</a>, <a href='https://seekingalpha.com/symbol/PEK' title='VanEck Vectors ChinaAMC CSI 300 ETF'>PEK</a>, <a href='https://seekingalpha.com/symbol/CHN' title='China Fund'>CHN</a>, <a href='https://seekingalpha.com/symbol/TDF' title='Templeton Dragon Fund'>TDF</a>, <a href='https://seekingalpha.com/symbol/KBA' title='KraneShares Bosera MSCI China A ETF'>KBA</a>, <a href='https://seekingalpha.com/symbol/QQQC' title='Global X China Technology ETF'>QQQC</a>, <a href='https://seekingalpha.com/symbol/XPP' title='ProShares Ultra FTSE China 25 ETF'>XPP</a>, <a href='https://seekingalpha.com/symbol/CHAU' title='Direxion Daily CSI 300 China A Share Bull 2x Shares ETF'>CHAU</a>, <a href='https://seekingalpha.com/symbol/YXI' title='ProShares Short FTSE China 50 ETF'>YXI</a>, <a href='https://seekingalpha.com/symbol/CN' title='Deutsche X-trackers Harvest MSCI All China Equity ETF'>CN</a>, <a href='https://seekingalpha.com/symbol/FCA' title='First Trust China AlphaDEX ETF'>FCA</a>, <a href='https://seekingalpha.com/symbol/YAO' title='Guggenheim China All-Cap ETF'>YAO</a>, <a href='https://seekingalpha.com/symbol/CHAD' title='Direxion Daily CSI 300 China A Share Bear 1x Shares ETF'>CHAD</a>, <a href='https://seekingalpha.com/symbol/GCH' title='Greater China Fund'>GCH</a>, <a href='https://seekingalpha.com/symbol/CXSE' title='WisdomTree China ex-State-Owned Enterprises ETF'>CXSE</a>, <a href='https://seekingalpha.com/symbol/JFC' title='JPMorgan China Region Fund, Inc.'>JFC</a>, <a href='https://seekingalpha.com/symbol/ECNS' title='iShares MSCI China Small-Cap ETF'>ECNS</a>, <a href='https://seekingalpha.com/symbol/AFTY' title='CSOP FTSE China A50 ETF'>AFTY</a>, <a href='https://seekingalpha.com/symbol/CWEB' title='Direxion Daily CSI China Internet Index Bull 2x Shares ETF'>CWEB</a>, <a href='https://seekingalpha.com/symbol/ASHX' title='Deutsche X-trackers CSI 300 China A-Shares Hedged Equity ETF'>ASHX</a>, <a href='https://seekingalpha.com/symbol/CNYA' title='iShares MSCI China A ETF'>CNYA</a>, <a href='https://seekingalpha.com/symbol/HAHA' title='CSOP China CSI 300 A-H Dynamic ETF'>HAHA</a>, <a href='https://seekingalpha.com/symbol/CNHX' title='CSOP MSCI China A International Hedged ETF'>CNHX</a>, <a href='https://seekingalpha.com/symbol/XINA' title='SPDR MSCI China A Shares IMI ETF'>XINA</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3278951\" data-linked=\"&#39;Black Monday&#39; in China\" data-tweet=\"$CNXT $ASHS $FXI - &#39;Black Monday&#39; in China https://seekingalpha.com/news/3278951-black-monday-in-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3278951-black-monday-in-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278949\" data-ts=\"1500303719\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLDQ\" target=\"_blank\">SHLDQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278949-sears-lands-200m-credit-line-from-ceo-lamperts-hedge-fund-sharesplus-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sears lands $200M credit line from CEO Lampert&#39;s hedge fund; shares +9%</a></h4><ul><li>Sears (SHLD <font color='green'>+8.6%</font>) surges nearly 10% after disclosing it obtained a <a href=\"https://www.sec.gov/Archives/edgar/data/923727/000119312517228970/d416624dsc13da.htm\" target=\"_blank\">new $200M line of credit</a> from CEO Eddie Lampert's hedge fund.</li><li>Lampert's ESL Partners entered into a short-term line of credit loans,  which carry a maturity date of 151 days and a 9.75% fixed annual interest rate.</li><li>Cash injections from Lampert's hedge fund and his heavy ownership of the  company's unsecured debt continue to convince some investors that SHLD will <a href=\"http://www.cnbc.com/2017/07/17/sears-inks-200-million-credit-line-from-ceo-eddie-lamperts-hedge-fund.html\" target=\"_blank\">avoid filing Chapter 11</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278949\" data-linked=\"Sears lands $200M credit line from CEO Lampert&#39;s hedge fund; shares +9%\" data-tweet=\"$SHLDQ - Sears lands $200M credit line from CEO Lampert&#39;s hedge fund; shares +9% https://seekingalpha.com/news/3278949-sears-lands-200m-credit-line-from-ceo-lamperts-hedge-fund-sharesplus-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3278949-sears-lands-200m-credit-line-from-ceo-lamperts-hedge-fund-sharesplus-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>67&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278925\" data-ts=\"1500303674\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278925-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/SNGX' title='Soligenix, Inc.'>SNGX</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/QDEL' title='Quidel Corporation'>QDEL</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics'>CBAY</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> PPHM <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD'>TXMD</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color='red'>-10%</font>. NVGN <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/RDUS' title='Radius Health, Inc.'>RDUS</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278925\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$ACRX $SNGX $QDEL - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3278925-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3278925-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278946\" data-ts=\"1500303255\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCH\" target=\"_blank\">FCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278946-rlj-lodgingplus-9-on-buyout-offer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RLJ Lodging +9% on buyout offer</a></h4><ul><li><a href=\"https://seekingalpha.com/filing/3626479\" target=\"_blank\">In a filing relating</a> to its upcoming buyout of FelCor Lodging (<a href='https://seekingalpha.com/symbol/FCH' title='FelCor Lodging Trust'>FCH</a> <font color='red'>-2.1%</font>), RLJ Lodging (<a href='https://seekingalpha.com/symbol/RLJ' title='RLJ Lodging Trust'>RLJ</a> <font color='green'>+9.2%</font>) says it received a purchase proposal from a Party Y (a P-E firm) for $24 per share. With today's gain, the stock's trading at $21.44.</li><li>The board rejected the offer, saying it's not likely to lead to a superior proposal to its purchase of FelCor.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278946\" data-linked=\"RLJ Lodging +9% on buyout offer\" data-tweet=\"$FCH $FCH $RLJ - RLJ Lodging +9% on buyout offer https://seekingalpha.com/news/3278946-rlj-lodgingplus-9-on-buyout-offer?source=tweet\" data-url=\"https://seekingalpha.com/news/3278946-rlj-lodgingplus-9-on-buyout-offer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278945\" data-ts=\"1500303216\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAPS\" target=\"_blank\">CAPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278945-capstone-secures-3_44m-in-new-capital-shares-ahead-26\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capstone secures $3.44M in new capital; shares ahead 26%</a></h4><ul><li>Capstone Therapeutics (<a href='https://seekingalpha.com/symbol/CAPS' title='Capstone Therapeutics Corp'>OTC:CAPS</a> <font color='green'>+25.5%</font>) <a href=\"https://seekingalpha.com/pr/16887769-capstone-therapeutics-announces-transaction-sale-shares-common-stock-secured-loan\" target=\"_blank\">announces </a>the direct sale of 13.5M shares of common stock to BP Peptides, LLC at $0.075 per share (~$1.013M). BP also provided a $2,427,500 secured loan to the company at 6%.</li><li>Proceeds will fund Capstone's operations, its joint venture LipimetiX Development and the retirement of certain convertible debt.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278945\" data-linked=\"Capstone secures $3.44M in new capital; shares ahead 26%\" data-tweet=\"$CAPS - Capstone secures $3.44M in new capital; shares ahead 26% https://seekingalpha.com/news/3278945-capstone-secures-3_44m-in-new-capital-shares-ahead-26?source=tweet\" data-url=\"https://seekingalpha.com/news/3278945-capstone-secures-3_44m-in-new-capital-shares-ahead-26\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278939\" data-ts=\"1500301913\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278939-tesla-down-another-3-autopilot-blamed-after-minnesota-incident\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla down another 3%; autopilot blamed after Minnesota incident</a></h4><ul><li>Those looking for an excuse for the latest decline in the stock will find a report <a href=\"http://www.startribune.com/twin-cities-man-blames-autopilot-after-tesla-rolls-into-marsh/434941843/\" target=\"_blank\">from the Twin Cities of</a> sudden acceleration leading to the overturning of a Tesla in a marsh. Four in the vehicle at the time were slightly hurt.</li><li>The crash occurred after the autopilot feature was engaged, according to the driver.</li><li><a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>&nbsp;<font color='red'>-3.25%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3278939\" data-linked=\"Tesla down another 3%; autopilot blamed after Minnesota incident\" data-tweet=\"$TSLA - Tesla down another 3%; autopilot blamed after Minnesota incident https://seekingalpha.com/news/3278939-tesla-down-another-3-autopilot-blamed-after-minnesota-incident?source=tweet\" data-url=\"https://seekingalpha.com/news/3278939-tesla-down-another-3-autopilot-blamed-after-minnesota-incident\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>170&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278937\" data-ts=\"1500301534\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAH\" target=\"_blank\">BAH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278937-booz-allen-down-2_2-after-jefferies-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Booz Allen down 2.2% after Jefferies downgrade</a></h4><ul><li>The overhang from the <a href=\"https://seekingalpha.com/news/3274034-sell-side-mulls-booz-allen-probe-bail-shares-plunge-19-percent\" target=\"_blank\">DOJ investigation</a> is scaring off analyst&nbsp;Sheila Kahyaoglustrq, who cuts to Hold from Buy.</li><li>The decline in the stock since the probe leaked suggests investors are pricing in a $500M penalty and the loss of some new business, she says. Similar overhangs in the past have tended to last 6-9 months, meaning another 5-8 months of difficulty for the stock.</li><li>Kahyaoglustrq cuts the price target to $36 from $41, still nearly 10% upside from the current $33.09.</li><li>Source: Bloomberg</li><li><a href='https://seekingalpha.com/symbol/BAH' title='Booz Allen Hamilton Holding Corporation'>BAH</a><font color='red'> -2.2%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3278937\" data-linked=\"Booz Allen down 2.2% after Jefferies downgrade\" data-tweet=\"$BAH - Booz Allen down 2.2% after Jefferies downgrade https://seekingalpha.com/news/3278937-booz-allen-down-2_2-after-jefferies-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3278937-booz-allen-down-2_2-after-jefferies-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278935\" data-ts=\"1500301443\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONCE\" target=\"_blank\">ONCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278935-fda-accepts-sparks-marketing-application-for-gene-therapy-for-retinal-disease-action-date\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Spark&#39;s marketing application for gene therapy for retinal disease, action date January 12; shares ahead 3%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16887666-spark-therapeutics-biologics-license-application-investigational-voretigene-neparvovec\" target=\"_blank\">accepts for review</a> Spark Therapeutics' (<a href='https://seekingalpha.com/symbol/ONCE' title='Spark Therapeutics'>ONCE</a> <font color='green'>+2.7%</font>) Biologics License Application &#40;BLA&#41; seeing approval of gene therapy LUXTURNA (voretigene neparvovec) for the treatment of patients with vision loss due to bialletic RPE65-mediated inherited retinal disease. The agency's action date is January 12, 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278935\" data-linked=\"FDA accepts Spark&#39;s marketing application for gene therapy for retinal disease, action date January 12; shares ahead 3%\" data-tweet=\"$ONCE - FDA accepts Spark&#39;s marketing application for gene therapy for retinal disease, action date January 12; shares ahead 3% https://seekingalpha.com/news/3278935-fda-accepts-sparks-marketing-application-for-gene-therapy-for-retinal-disease-action-date?source=tweet\" data-url=\"https://seekingalpha.com/news/3278935-fda-accepts-sparks-marketing-application-for-gene-therapy-for-retinal-disease-action-date\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278933\" data-ts=\"1500300853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCI\" target=\"_blank\">CCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278933-crown-castle-lower-after-report-of-7b-plus-lightower-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crown Castle lower after report of $7B-plus Lightower bid</a></h4><ul>   <li>Crown Castle International (<a href=\"http://seekingalpha.com/symbol/CCI\" target=\"_blank\">CCI</a> <font color='red'>-1.9%</font>) has opened lower after weekend word that it's offered to <a href=\"http://www.reuters.com/article/us-lightower-m-a-crown-castle-idUSKBN19Z2JD\" target=\"_blank\">buy Lightower Fiber Networks</a> in what would be its biggest acquisition.</li>    <li>The company offered more than $7B including debt, Reuters reports, and would add substantial fiber assets to a company built on communications towers. Sealing the deal would mean prevailing over less well-funded rivals like Uniti Group (<a href=\"http://seekingalpha.com/symbol/UNIT\" target=\"_blank\">UNIT</a> <font color='green'>+0.8%</font>).</li>    <li>A deal could come as soon as this month after Lightower majority owner Berkshire Partners studies the bid, the report says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278933\" data-linked=\"Crown Castle lower after report of $7B-plus Lightower bid\" data-tweet=\"$CCI $CCI $UNIT - Crown Castle lower after report of $7B-plus Lightower bid https://seekingalpha.com/news/3278933-crown-castle-lower-after-report-of-7b-plus-lightower-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3278933-crown-castle-lower-after-report-of-7b-plus-lightower-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278932\" data-ts=\"1500300824\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RZLT\" target=\"_blank\">RZLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278932-antriabio-closes-private-13m-capital-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AntriaBio closes private $13M capital raise</a></h4><ul><li>Thinly traded nano cap AntriaBio (ANTB <font color='green'>+0.9%</font>) <a href=\"https://seekingalpha.com/pr/16887693-antriabio-announces-13-million-close-private-placement-transaction-plan-dose-first-patient\" target=\"_blank\">finalizes </a>its private placement of common stock at $1 per share, raising $13M in new capital. Net proceeds will be used for general corporate purposes.</li><li>Friday's close was $1.14.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278932\" data-linked=\"AntriaBio closes private $13M capital raise\" data-tweet=\"$RZLT - AntriaBio closes private $13M capital raise https://seekingalpha.com/news/3278932-antriabio-closes-private-13m-capital-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3278932-antriabio-closes-private-13m-capital-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278914\" data-ts=\"1500298069\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VHC\" target=\"_blank\">VHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278914-virnetx-shares-plunge-after-stock-sale-postponement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VirnetX shares plunge after stock sale postponement</a></h4><ul><li>        VirnetX (NYSEMKT:<a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a>) announces that a previously announced share purchase agreement will not complete today as expected due to financing issues.</li><li>               Early last month, VirnetX announced that Public Intelligence Technology Associates would purchase nearly 5.5M shares of common stock for a purchase price around $20M.&nbsp;</li><li>               The new <a href=\"https://seekingalpha.com/filing/3625994\" target=\"_blank\">regulatory filing</a> says the sale can&rsquo;t complete on July 17 as planned because the investor&rsquo;s &ldquo;financing sources have not yet completed their diligence of Investor&rdquo; and that the company still believes the sale will occur in the future. &nbsp;&nbsp;</li><li>               VirnetX shares are&nbsp;<font color='red'>down 22.83%</font>&nbsp;premarket.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3278914\" data-linked=\"VirnetX shares plunge after stock sale postponement\" data-tweet=\"$VHC - VirnetX shares plunge after stock sale postponement https://seekingalpha.com/news/3278914-virnetx-shares-plunge-after-stock-sale-postponement?source=tweet\" data-url=\"https://seekingalpha.com/news/3278914-virnetx-shares-plunge-after-stock-sale-postponement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278913\" data-ts=\"1500298036\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LABL\" target=\"_blank\">LABL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278913-multi-color-to-buy-constantia-labels-division-in-1_3b-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Multi-Color to buy Constantia Labels division in $1.3B deal</a></h4><ul>     <li>Multi-Color Corp. (NASDAQ:<a href='https://seekingalpha.com/symbol/LABL' title='Multi-Color Corporation'>LABL</a>) <font color='red'>-5.8%</font> premarket after agreeing to acquire the Labels division of Constantia Flexibles for $1.3B (&euro;1.15B) in cash and stock.</li>     <li>LABL says the combination brings together its wine and spirits and home and personal care platforms with Constantia Labels' food  and beverage business.</li>     <li>LABL expects cost synergies from the deal to reach $15M, or 2% of acquired revenues, by FY 2020.</li><li>LABL also reaffirms core  EPS guidance of $4.00 for  FY 2018 of $4.00 and $0.80 for the June quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278913\" data-linked=\"Multi-Color to buy Constantia Labels division in $1.3B deal\" data-tweet=\"$LABL - Multi-Color to buy Constantia Labels division in $1.3B deal https://seekingalpha.com/news/3278913-multi-color-to-buy-constantia-labels-division-in-1_3b-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3278913-multi-color-to-buy-constantia-labels-division-in-1_3b-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278911\" data-ts=\"1500297979\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBAY\" target=\"_blank\">CBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278911-cymabays-seladelpar-shows-positive-treatment-effect-in-mid-stage-pbc-study-shares-ahead-17\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CymaBay&#39;s seladelpar shows positive treatment effect in mid-stage PBC study; shares ahead 17% premarket</a></h4><ul><li>Thinly traded micro cap CymaBay Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics'>CBAY</a>) is up&nbsp;<font color='green'>17%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16887672-cymabay-announces-positive-interim-results-ongoing-low-dose-phase-2-study-seladelpar-patients\" target=\"_blank\">announcement </a>of positive interim results from a Phase 2 clinical trial assessing seladelpar in patients with primary biliary cholangitis &#40;PBC&#41;.</li><li>24 patients at high risk of disease progression who received 12 weeks of treatment with seladelpar showed significant reductions in the liver enzyme alkaline phosphatase &#40;AP&#41;, specifically, 39% and 45%, respectively, in the 5 mg and 10 mg groups. AP is a surrogate marker for disease progression in PBC.</li><li>In addition, patients in both dose groups experienced decreases in two other liver markers for impaired bile flow, gamma glutamyl transferase and total bilirubin, as well as improved metabolic and inflammatory markers.</li><li>No safety signals were observed at either dose.</li><li>The FDA has agreed to allow the continuation of treatment beyond six months for both doses.</li><li>Orphan Drug-tagged seladelpar is a potent, selective, orally active PPAR&delta; agonist that is in development for the treatment of the liver diseases PBC and nonalcoholic steatohepatitis &#40;NASH&#41;.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278911\" data-linked=\"CymaBay&#39;s seladelpar shows positive treatment effect in mid-stage PBC study; shares ahead 17% premarket\" data-tweet=\"$CBAY - CymaBay&#39;s seladelpar shows positive treatment effect in mid-stage PBC study; shares ahead 17% premarket https://seekingalpha.com/news/3278911-cymabays-seladelpar-shows-positive-treatment-effect-in-mid-stage-pbc-study-shares-ahead-17?source=tweet\" data-url=\"https://seekingalpha.com/news/3278911-cymabays-seladelpar-shows-positive-treatment-effect-in-mid-stage-pbc-study-shares-ahead-17\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278910\" data-ts=\"1500297642\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278910-blue-apronminus-7-amazon-signals-move-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blue Apron -7% as Amazon signals move into business</a></h4><ul><li>\"We do the prep. You be the chef.\" So goes a trademark application from Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) on plans for \"prepared food kits composed of meat, poultry, fish, seafood, fruit and/or vegetables...ready for cooking and assembly as a meal.\"</li><li>Source: <a href=\"https://www.thestreet.com/story/14230261/1/amazon-getting-into-meal-kits-continuing-to-dominate-blue-apron.html\" target=\"_blank\">Laura Berman at The Street</a></li><li><a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a>&nbsp;<font color='red'>-7.2%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3278910\" data-linked=\"Blue Apron -7% as Amazon signals move into business\" data-tweet=\"$AMZN $AMZN $APRN - Blue Apron -7% as Amazon signals move into business https://seekingalpha.com/news/3278910-blue-apronminus-7-amazon-signals-move-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3278910-blue-apronminus-7-amazon-signals-move-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278907\" data-ts=\"1500297079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278907-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='green'>+25%</font>.</li><li><a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+15%</font>.</li><li><a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd'>MDGS</a> <font color='green'>+14%</font>.</li><li><a href='https://seekingalpha.com/symbol/BGC' title='General Cable Corporation'>BGC</a>&nbsp;<font color='green'>+8%</font>&nbsp;on initiating review of strategic alternatives.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278907\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$TEUM $ACRX $MDGS - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3278907-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3278907-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278906\" data-ts=\"1500297041\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278906-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD'>TXMD</a>&nbsp;<font color='red'>-13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3278873-therapeuticsmd-submits-crl-related-data-fda-review-timeline-undetermined-shares-7-percent\" target=\"_blank\">announcing</a> regulatory update on TX-004HR.</li><li><a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a> <font color='red'>-8%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3278906\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$TXMD $APRN - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3278906-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3278906-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278904\" data-ts=\"1500296865\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRX\" target=\"_blank\">AMRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278904-fda-oks-impax-labs-generic-concerta-shares-ahead-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Impax Labs&#39; generic Concerta; shares ahead 6% premarket</a></h4><ul><li>Impax Laboratories (IPXL) is up&nbsp;<font color='green'>6%</font>&nbsp;premarket, albeit on only 750 shares, on the heels of its announcement that the FDA has <a href=\"https://seekingalpha.com/pr/16887664-impax-announces-fda-approval-ab-rated-generic-concerta-methylphenidate-hydrochloride-extended\" target=\"_blank\">approved </a>its &nbsp;generic version of Johnson &amp; Johnson's ADHD med Concerta (methylphenidate hydrochloride) Extended-Release tablets.</li><li>Per IMS Health, the U.S. market is ~$1.8B.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278904\" data-linked=\"FDA OKs Impax Labs&#39; generic Concerta; shares ahead 6% premarket\" data-tweet=\"$AMRX - FDA OKs Impax Labs&#39; generic Concerta; shares ahead 6% premarket https://seekingalpha.com/news/3278904-fda-oks-impax-labs-generic-concerta-shares-ahead-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3278904-fda-oks-impax-labs-generic-concerta-shares-ahead-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278901\" data-ts=\"1500296410\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDGS\" target=\"_blank\">MDGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278901-medigus-up-15-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medigus up 15% premarket</a></h4><ul><li>Thinly traded nano cap Medigus Ltd. (NASDAQ:<a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd'>MDGS</a>) is up&nbsp;<font color='green'>15%</font>&nbsp;premarket on increased volume. No particular news accounts for the move. Several months ago it announced the launch of MUSE procedures in China.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3260683-muse-procedures-advancing-china-medigus-18-percent-premarket\" target=\"_blank\">MUSE procedures advancing in China; Medigus up 18% premarket</a> (April 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3278901\" data-linked=\"Medigus up 15% premarket\" data-tweet=\"$MDGS - Medigus up 15% premarket https://seekingalpha.com/news/3278901-medigus-up-15-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3278901-medigus-up-15-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278900\" data-ts=\"1500296336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XPO\" target=\"_blank\">XPO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278900-xpo-logisticsminus-3_6-on-11m-share-offering-preliminary-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XPO Logistics -3.6% on 11M-share offering, preliminary Q2 results</a></h4><ul><li>XPO&nbsp;Logistics (NYSEMKT:<a href='https://seekingalpha.com/symbol/XPO' title='XPO Logistics, Inc'>XPO</a>) <font color='red'>-3.6%</font> premarket after <a href=\"https://seekingalpha.com/filing/3626399\" target=\"_blank\">disclosing</a> plans to make an offering of 11M common shares in an underwritten offering.</li><li>XPO expects to use the proceeds for general corporate purposes, which may include strategic acquisitions and the repayment or refinancing of outstanding indebtedness.</li><li>XPO also pre-announces Q2 revenues of $3.75B-$3.76B vs. $3.74B analyst consensus estimate, operating income of $183M-$187M and Y/Y organic revenue growth of 7%-7.9%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278900\" data-linked=\"XPO Logistics -3.6% on 11M-share offering, preliminary Q2 results\" data-tweet=\"$XPO - XPO Logistics -3.6% on 11M-share offering, preliminary Q2 results https://seekingalpha.com/news/3278900-xpo-logisticsminus-3_6-on-11m-share-offering-preliminary-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3278900-xpo-logisticsminus-3_6-on-11m-share-offering-preliminary-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278892\" data-ts=\"1500295373\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278892-teva-targeted-european-regulators-for-pay-for-delay-deal-cephalon-shares-off-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva targeted by European regulators for pay-for-delay deal with Cephalon; shares off 1% premarket</a></h4><ul><li>Reuters <a href=\"http://www.reuters.com/article/us-wellsfargo-business-idUSKBN1A10TN?il=0&amp;utm_source=hs_email&amp;utm_medium=email&amp;utm_content=54289863&amp;_hsenc=p2ANqtz-9ouNnvKoGoINycTuSCWqwXcf9gJwlqv2VzZ7Cfn9F4AIfD0v-5qltvxYGoyN5Z5I9siBhodFiaFEIy0TK-lL_Y0lIPQA&amp;_hsmi=54289863\" target=\"_blank\">reports </a>that EU antitrust regulators have charged Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) with executing an illegal deal with Cephalon to delay the market launch if a generic version of its sleep disorder drug modafinil. The Israeli drug makers could be at risk of a fine in the matter, possibly as high as 10% of its global sales.</li><li>The Teva/Cephalon deal pertained to a cash settlement over the alleged infringement of certain Cephalon patents. Teva later acquired Cephalon in 2011.</li><li>Over the past several years, the European Commission has fined a number of companies, including Johnson &amp; Johnson, Lundbeck and Servier, over similar deals.</li><li>Teva says it strongly disagrees with the Commission's position.</li><li>Shares are down&nbsp;<font color='red'>1%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278892\" data-linked=\"Teva targeted by European regulators for pay-for-delay deal with Cephalon; shares off 1% premarket\" data-tweet=\"$TEVA - Teva targeted by European regulators for pay-for-delay deal with Cephalon; shares off 1% premarket https://seekingalpha.com/news/3278892-teva-targeted-european-regulators-for-pay-for-delay-deal-cephalon-shares-off-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3278892-teva-targeted-european-regulators-for-pay-for-delay-deal-cephalon-shares-off-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278873\" data-ts=\"1500293065\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TXMD\" target=\"_blank\">TXMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278873-therapeuticsmd-submits-crl-related-data-to-fda-review-timeline-undetermined-shares-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TherapeuticsMD submits CRL-related data to FDA, review timeline undetermined; shares down 7% premarket</a></h4><ul><li>TherapeuticsMD (NYSEMKT:<a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD'>TXMD</a>) slips&nbsp;<font color='red'>7%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16887593-therapeuticsmd-provides-txminus-004hr-regulatory-update\" target=\"_blank\">announcement </a>that it has received the minutes from its Type A Post-Action Meeting with the FDA review team regarding the issues raised in the Complete Response Letter &#40;CRL&#41; it received in May related to its NDA for TX-004HR, an applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse.</li><li>The company has formally submitted the responses cited in the CRL. A formal timeline for review has yet to be determined, but the company expects to receive clarity from the FDA in the coming weeks.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3264538-therapeuticsmd-address-fda-concerns-txminus-004hr\" target=\"_blank\">TherapeuticsMD to address FDA concerns on TX-004HR</a> (May 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3278873\" data-linked=\"TherapeuticsMD submits CRL-related data to FDA, review timeline undetermined; shares down 7% premarket\" data-tweet=\"$TXMD - TherapeuticsMD submits CRL-related data to FDA, review timeline undetermined; shares down 7% premarket https://seekingalpha.com/news/3278873-therapeuticsmd-submits-crl-related-data-to-fda-review-timeline-undetermined-shares-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3278873-therapeuticsmd-submits-crl-related-data-to-fda-review-timeline-undetermined-shares-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278872\" data-ts=\"1500292356\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBHT\" target=\"_blank\">JBHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278872-j-b-hunt-transport-services-down-on-earnings-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.B. Hunt Transport Services down on earnings miss</a></h4><ul>     <li>J.B. Hunt Transport Services (NASDAQ:<a href='https://seekingalpha.com/symbol/JBHT' title='J.B. Hunt Transport Services, Inc.'>JBHT</a>)&nbsp;reports total operating revenue (excl. fuel surcharges) rose 5% to $1.55B in <a href=\"https://seekingalpha.com/pr/16887676-j-b-hunt-transport-services-inc-reports-earnings-second-quarter-2017-updates-full-year-2017\" target=\"_blank\">Q2</a>.</li>     <li>Segment revenue:&nbsp;Intermodal: $1B (+7%);&nbsp;Dedicated&nbsp;Contract Services: $411.92M&nbsp;(+8%);&nbsp;Integrated Capacity Solutions: $222.47M (+9%); Truck: $94.58M (-4%).</li>     <li>Segment income:&nbsp;Intermodal: $109.71M (+4%);&nbsp;Dedicated: $48.57M (-4%);&nbsp;Integrated Capacity Solutions: -$0.24M (-102%); Truck: $5.56M (-37%).</li>     <li>Operating margin rate fell 140 bps to 9.5%.</li>     <li>Total tractors in operation -110 Y/Y to 2,072</li>     <li>Total trailers in operation +355 Y/Y to 7,604.</li>     <li>The company expects annual tax rate of ~35% in FY2017.</li>     <li>JBHT&nbsp;<font color='red'>-2.07%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278872\" data-linked=\"J.B. Hunt Transport Services down on earnings miss\" data-tweet=\"$JBHT - J.B. Hunt Transport Services down on earnings miss https://seekingalpha.com/news/3278872-j-b-hunt-transport-services-down-on-earnings-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3278872-j-b-hunt-transport-services-down-on-earnings-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278869\" data-ts=\"1500292054\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RPRX\" target=\"_blank\">RPRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278869-repros-proellex-program-to-remain-on-partial-clinical-hold-pending-compilation-of-large\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Repros&#39; Proellex program to remain on partial clinical hold pending compilation of large safety database; shares slump 48% premarket</a></h4><ul><li>Nano cap Repros Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RPRX' title='Repros Therapeutics Inc.'>RPRX</a>) craters&nbsp;<font color='red'>48%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16887578-repros-announces-proellex-development-program-will-remain-partial-clinical-hold-fda\" target=\"_blank\">announcement </a>that the FDA will maintain its partial clinical hold on its Proellex (telapristone acetate)&nbsp;program after reviewing the existing liver function safety data. The company will be required to compile a large pre-approval safety data set in order to support further development. In other words, a much larger clinical trial will be necessary.</li><li>Considering the time and expense of an new clinical study, the company is mulling increasing its focus on the uterine fibroid and endometriosis indications using a vaginal drug delivery approach. It also will assess drug delivery technology that will enable less frequent dosing than once per day.</li><li><a href=\"http://www.reprosrx.com/proellex.php\" target=\"_blank\">Proellex</a>&nbsp;is a small molecule compound that selectively blocks the progesterone receptor.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3256370-fda-continues-partial-clinical-hold-repros-therapeutics-fibroids-drug\" target=\"_blank\">FDA continues partial clinical hold for Repros Therapeutics' fibroids drug</a> (April 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3278869\" data-linked=\"Repros&#39; Proellex program to remain on partial clinical hold pending compilation of large safety database; shares slump 48% premarket\" data-tweet=\"$RPRX - Repros&#39; Proellex program to remain on partial clinical hold pending compilation of large safety database; shares slump 48% premarket https://seekingalpha.com/news/3278869-repros-proellex-program-to-remain-on-partial-clinical-hold-pending-compilation-of-large?source=tweet\" data-url=\"https://seekingalpha.com/news/3278869-repros-proellex-program-to-remain-on-partial-clinical-hold-pending-compilation-of-large\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278866\" data-ts=\"1500291622\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BGC\" target=\"_blank\">BGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278866-general-cable-initiates-review-of-strategic-alternatives\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">General Cable initiates review of strategic alternatives</a></h4><ul>     <li>General Cable (NYSE:<a href='https://seekingalpha.com/symbol/BGC' title='General Cable Corporation'>BGC</a>) <font color='green'>+3%</font> premarket after announcing yesterday a <a href=\"https://seekingalpha.com/pr/16887483-general-cable-announces-review-strategic-alternatives-maximize-shareholder-value\" target=\"_blank\">review of strategic alternatives</a> that could include a potential sale of the company.</li><li>BGC also unveils preliminary Q2 results, expecting to report $923M in revenues for North America, Europe  and Latin America, and foresees a $23M operating  loss.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3278866\" data-linked=\"General Cable initiates review of strategic alternatives\" data-tweet=\"$BGC - General Cable initiates review of strategic alternatives https://seekingalpha.com/news/3278866-general-cable-initiates-review-of-strategic-alternatives?source=tweet\" data-url=\"https://seekingalpha.com/news/3278866-general-cable-initiates-review-of-strategic-alternatives\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:40 AM </div></div></li>","count":57,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}